The biotech firm highlighted in today’s article, which in the past year has refocused its efforts on a newer cancer-fighting technology, is the No. 4 best-performing stock on the Nasdaq Composite Index and the No. 1 best-performing stock on Canada’s S&P/TSX Composite Index – and despite having already experienced a 3,600% surge, the author notes that “every analyst covering the company rates it a buy, signaling that further gains are on the horizon for investors that missed out on [its] initial boom.” For more on this biotech – which is speculated could be an M&A target – CLICK HERE.
Missed Out On This Biotech’s 3,600% Surge? Further Gains May Be On The Horizon
Tags:Biotech InvestorsBiotech StocksBiotech SurgeBuy SignalsCompany RatesComposite IndexInvestInvestinginvestorsM&A TargetS&PStock MarketTSX